Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Sorafenib (Nexavar) in Metastatic Advanced Thyroid Cancer
2006-006615-80Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in well-differentiated thyroid cancer (WDTC) and Medullary Thyroid Cancer (MTC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Objective overall response within 6 months. Started Jan 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
well-differentiated thyroid cancer (WDTC)Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2006-006615-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006615-80.